| dc.contributor.author | Darshana, T. | |
| dc.contributor.author | Bandara, D. | |
| dc.contributor.author | Nawarathne, U. | |
| dc.contributor.author | de Silva, U. | |
| dc.contributor.author | Premawardhena, A. | |
| dc.date.accessioned | 2022-08-31T04:00:36Z | |
| dc.date.available | 2022-08-31T04:00:36Z | |
| dc.date.issued | 2020 | |
| dc.identifier.citation | Darshana, T., et al. (2020). Sickle cell disease in Sri Lanka: clinical and molecular basis and the unanswered questions about disease severity. Orphanet Journal of Rare Diseases (2020) 15:177 | en_US |
| dc.identifier.uri | http://dr.lib.sjp.ac.lk/handle/123456789/11866 | |
| dc.description.abstract | Background: Though case reports and limited case series of Sickle cell disease in Sri Lanka have been reported previously, no attempt has been made hitherto to undertake a comprehensive genotypic-phenotypic analysis of this “rare” group of patients. Results: All accessible Sickle cell disease patients, totaling 60, including, 51 Sickle β-thalassaemia and 9 homozygous sickle patients were enrolled from seven thalassaemia treatment centres between December 2016–March 2019. The majority of patients were of Sinhalese ethnicity (n = 52, 86.67%). Geographically, two prominent clusters were identified and the distribution of Sickle haemoglobin in the island contrasted markedly with the other haemoglobinopathies. 3/ 9 homozygous sickle patients and 3/ 51 Sickle β-thalassaemia patients were receiving regular transfusion. Joint pain was the commonest clinical symptom among all sickle cell disease patients (n = 39, 65.0%). Dactylitis was significantly more common in homozygous sickle patients compared with the Sickle β-thalassaemia groups (p 0.027). Two genetic backgrounds sickle mutation were identified namely, Arab Indian and Benin. Among the regulators of Foetal hemoglobin in Sickle patients of the present study rs1427407 G > T seemed to be the most prominent modifier, with a significant association with Foetal haemoglobin levels (p 0.04). Conclusions: Overall, the clinical course of the Asian version of Sickle cell disease in Sri Lanka appears to be milder than that described in India | en_US |
| dc.language.iso | en | en_US |
| dc.subject | Sickle cell, Sri Lanka, Genetic, Clinical, Severity | en_US |
| dc.title | Sickle cell disease in Sri Lanka: clinical and molecular basis and the unanswered questions about disease severity | en_US |
| dc.type | Article | en_US |